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Introduction
Studies in iatrogenic CJD are extremely useful to under-
stand some aspects of infections in humans, as the infec-
tious agent may reach the brain via different routes: di-
rect inoculation (EEG depth electrodes), oral infection 
(growth hormone therapy, vCJD), peripheral infection 
(blood transfusion) and superficial infection (dura ma-
ter and corneal transplant). 
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■ Abstract  Objective Iatrogenic 
Creutzfeldt-Jakob disease (iCJD) is 
mainly associated with dura mater 
(DM) grafts and administration of 
human growth hormones (hGH). 
Data on disease course in DM-CJD 
are limited. We describe the clinical 
and diagnostic findings in this pa-
tient group with special emphasis 
on MRI signal alterations. Methods 
Ten DM-CJD patients were studied 
for their clinical symptoms and 
 diagnostic findings. The MRIs were 
evaluated for signal increase of the 
cortical and subcortical structures. 
Results DM-CJD patients had a 
 median incubation time of 18 years 
and median disease duration of 7 
months. The majority of patients 
were MM homozygous at codon 
129 of the prion protein gene 
(PRNP) and presented with gait 
ataxia and psychiatric symptoms. 
No correlation between the graft 
site and the initial disease course 
was found. The MRI showed corti-
cal and basal ganglia signal in-
crease each in eight out of ten pa-
tients and thalamic hyperintensity 
in five out of ten cases. Of interest, 
patients with thalamic signal in-
crease were homozygous for me-
thionine. Conclusion The MRI find-
ings in DM-CJD largely resemble 
those seen in sporadic CJD, as the 
cortex and basal ganglia are mainly 
affected.
■ Key words  CJD · MRI · 
dementia · cerebellar disorder · 
CNS infection
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The diagnosis of iCJD is based on the presence of 
typical symptoms (dementia, ataxia, extrapyramidal 
and pyramidal signs, myoclonus and akinetic mutism) 
and a history of iatrogenic exposure. The finding of 14-
3-3 protein in the CSF may support the diagnosis (77 % 
sensitivity) [1, 2].
Dura mater grafts have been found as disease cause 
in 200 CJD patients worldwide [1]. Due to the long incu-
bation periods ranging from 16 months to 31 years, DM-
CJD cases are still detected nowadays [1, 3–9]. 
Increased rates of early ataxia have been reported in 
DM-CJD, hGH-CJD and vCJD [10–13]. In DM-CJD, a 
possible influence of the graft location on the clinical 
onset has been suggested [14, 15]. Only limited data were 
reported on paraclinical tests in iCJD, such as MRI. Since 
the MRI pattern of high signal abnormalities follows the 
lesion pattern of the brain as detected by pathology, the 
analysis of MRI in iCJD might be extremely useful.
The goals of our study were to describe MRI and 
clinical findings in a larger number of DM-CJD patients 
and to correlate them with the graft location and codon 
129 genotype.
Methods
Patients with suspected CJD are reported to the CJD Surveillance Unit 
in Goettingen, (established in 1993) and examined by a study physi-
cian at the hospital reporting the case. A questionnaire about the pa-
tient’s history (profession, habits, meat consumption) is filled out and 
copies are made of the medical charts (clinical findings, laboratory 
tests, EEG and MRI). The patients are classified as possible, probable 
or no CJD case according to established criteria [16]. One Croatian 
case (case 10) was included in this study because material was sent for 
genetic analysis and all clinical data were available. 
■ Genetic analysis
Analysis of the prion protein gene (PRNP) was performed after isola-
tion of genomic DNA from blood according to standard methods 
[17]. PRNP mutations were excluded in all but one patient by full 
PRNP sequencing (case 9).
■ Neuropathology
Histological examination was performed according to standard 
methods [18, 20].
■ Clinical examination
The patients were examined for the presence of typical CJD symp-
toms at onset (within first month) and during the disease course. 
Symptoms representing a residual state after surgery were not in-
cluded in the analysis. Residual symptoms which progressed at the 
time of the disease onset were considered to be CJD signs and in-
cluded in the study.
■ MRI
MRIs were available in nine out of ten patients. All MR examinations 
had been obtained from a 1.5 Tesla scanner (a total of 11 T2w, 9 FLAIR 
(fluid attenuated inversion recovery), 6 PDw (proton density weighted 
imaging) and 4 DWI (diffusion-weighted imaging), including serial 
MRIs in four patients) and were mainly available as hardcopy. Digital 
MRI data were available in four patients (cases 2, 3, 5 and 8). The MRI 
scans were reported independently and in consensus by two neurora-
diologists (KK and MK) aware of the CJD diagnosis but not aware of 
the disease aetiology. The interobserver agreement was moderate for 
all the sequences (Concordance 80,. and κ = 0.52) and high for FLAIR 
(Concordance 83.6 and κ = 0.57), PDw (Concordance 83.3 and κ = 0.67) 
and DWI (Concordance 83.9 and κ = 0.65). The results of the consen-
sus review were used for the study.
 Using a standardized protocol, seven cortical areas (the frontal, 
parietal, temporal, occipital and insula cortex, as well as the cingulate 
gyrus and hippocampus), the basal ganglia (caudate nucleus, puta-
men, globus pallidus), the thalamus and the cerebellum were assessed 
for signal increase in relation to suspected normointense tissue.
Results
■ Patients with dura mater grafts
In the years 1993 to 2006, ten DM-CJD cases (four defi-
nite and six probable) were identified (nine in Germany, 
one in Croatia) (Table 1). All surgeries were performed 
between 1980 and 1987 (Fig. 1). The median age at onset 
was 55 years (range 25–70); the median disease duration 
was 8 months (range 2–30). Incubation periods ranged 
from 9 to 23 years (median 18 years) (Fig. 1). 
The codon 129 genotype was available in all patients 
(8 MM, 1 VV and 1 MV). Codon 219 was not examined 
in any case. The type of pathological prion protein (PrPSc 
1 or 2) was analyzed in three out of four autopsied cases 
(only formalin fixed brain tissue was available in one 
patient): Three patients displayed PrPSc type 1. In one 
further case, the PrPSc type could not be clearly identi-
fied as type one or two (case 7) (as previously discussed) 
[21] (Table 1). 
■ Clinical presentation
The main symptoms at onset (within the first month) 
and during the course of the disease are displayed in 
Table 2. Seven out of ten patients presented with gait 
ataxia (in three cases in isolation). Psychiatric abnor-
malities (depression and aggression) occurred in four 
out of ten patients (in one case as the only presenting 
symptom). Visual signs (double vision) were found in 
three patients, pyramidal signs (hemiparesis) in two and 
extrapyramidal signs (rigidity and choreatic move-
ments) in one out of ten patients. 
Only one patient displayed early signs of dementia. 
As unspecific clinical signs, vertigo (five patients) and 
headaches (five patients, data not displayed) were found 
most frequently. Further symptoms observed in the 
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early disease stage were dysaesthesias in three patients 
and loss of hearing, tinnitus, dysarthria, aphasia, abnor-
mal sense of taste in one patient each.
■ Time course of symptoms 
The median duration from the beginning of the disease 
to the onset of typical CJD symptoms is given in Fig. 2. 
Ataxia and psychiatric signs were among the earliest 
symptoms and followed by visual signs (median 1 
month) and dementia (median 2 months). Myoclonus, 
extrapayramidal and pyramidal signs were typical signs 
of the advanced disease stage (median 3 to 4 months). 
Akinetic mutism was found in only two patients.
■ Dura graft location and initial clinical symptoms
Details on the graft placement and the clinical signs are 
shown in Table 2.
Early ataxia occurred most frequently in patients 
with suboccipital graft (four cases) but also in three pa-
tients with different graft location. Psychiatric signs 
were predominant in patients with frontal graft (three 
cases) but also found in one patient with suboccipital 
graft. Two patients with early pyramidal signs (hemi-
paresis) had a dura graft in the parietal area. Early rigid-
ity was found in one patient with frontobasal graft. In 
four patients, the early disease course appeared to be 
monosymptomatic: three patients with suboccipital 
graft showed isolated ataxia for a time period of 4 weeks 
(case 9), 6 weeks (case 7) and 8 weeks (case 10). In one 
Table 1  Clinical and diagnostic data in ten dura-related iatrogenic CJD cases
Case Sex/age
(years)
Codon 129 genotype
(PrPSc type)
Cause for surgery CJD diagnosis
(WHO criteria)
Incubation
(years)
Disease duration
(months)
EEG:
PSWC
CSF:
14-3-3 
1 m/38 MV Brain trauma Probable 10  4 + +
2 m/44 MM (1) Brain trauma Definite 19 25 + +
3 f/70 MM Meningeoma Probable 19  3 – +
4 m/42 MM AV-angioma Probable 13  4 + +
5 m/54 MM Meningioma Probable 18 11 – +
6 f/56 MM (1) Acousticus neurinoma Definite  9  6 + +
7 m/57 MM Hemangioblastoma Definite 20 10 – +
8 f/65 MM Trigeminal neuralgia Probable 15 12 – +
9 f/64 MM (1) Pilocytic astrocytoma Definite 23  2 + +
10 f/25 VV Pilocytic astrocytoma Probable 17 30 (+) (–)
Median
55 years
Median 18  8 5/9 9/9
M male; f female; PSWC periodic sharp wave complexes
(+), (–) = assessed as positive or negative at the hospital reporting the case (not included in the present analysis)
17
23
15
20
9
18
13
19
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10
3
0
1
1
1
1
0
0
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1
Fig. 1  Incubation periods (years) and disease dura-
tion (months) in patients with dura mater graft
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further patient with frontobasal graft, only psychiatric 
signs were present for a time period of 6 months (case 
2). 
■ MRI
A synopsis of the MRI findings and applied sequences is 
given in Table 3. The cingulate gyrus was the most fre-
quently affected cortex region (eight out of ten), fol-
lowed by the frontal, temporal and parietal lobes (six out 
of ten, each).The occipital cortex was least affected 
(three out of ten). Basal ganglia hyperintensity was 
found in eight out of ten patients (in one case only dur-
ing follow-up), and thalamic hyperintensity in five (in 
three cases only on PDw). In one patient (MV type), no 
signal abnormalities were found (Fig. 3). The current 
criteria for a pulvinar- or hockey stick sign (pulvinar or 
dorsomedial thalamus brighter than the other grey mat-
ter) were not met in any of the patients [22, 23]. 
Two patients showed pronounced signal increase in 
the brain hemisphere containing the graft: In one pa-
tient with right temporal graft, the signal increase was 
more pronounced in the right temporal and parietal 
lobes (Case 4). In one patient with left suboccipital graft, 
the left frontal cortex appeared to be more hyperintense 
than on the right side (Case 10). In two other patients, 
the findings were reversed (signal more pronounced in 
the opposite brain hemisphere) (Cases 6 and 9).
Discussion
In a recent study on DM-CJD cases, MRI sensitivity was 
reported to be high but no details were given on the in-
volved brain areas [24]. According to a literature review, 
basal ganglia signal increase was found in eight out of 27 
patients [6, 8, 9, 21, 25, 26], additional cortical signal in-
crease in three [9, 25, 26] and thalamic hyperintensity in 
one [9]. In a large number of further cases, only atrophy 
was reported, which is most likely due to the less com-Ta
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Fig. 2  Time course of symptoms in patients with dura mater graft
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mon use of FLAIR and DW images in the past (Table 4) 
[3, 5–9, 21, 25–41]. 
We studied the MRI findings in ten iatrogenic CJD 
patients after dura mater transplant by highly sensitive 
sequences. Cortex involvement was found in all but two 
patients. The basal ganglia were affected in eight, the 
thalamus in five and the cerebellum in two cases. The 
majority of our patients was MM homozygous at codon 
129 of the PRNP and presented with gait ataxia.
At first sight, the MRI findings in our patients seem 
to largely resemble those seen in sporadic CJD. In sCJD, 
six molecular types (codon 129 genotype + PrPSc type 1 
or 2; MM1, MM2, MV1, MV2, VV1, VV2) have been de-
scribed with various clinical and diagnostic findings 
[42, 43]. Basal ganglia and cortical signal increase are 
most frequently found on the MRI [44–48]. Thalamic 
signal increase represents a comparatively rare finding, 
which seems to largely depend on the application of DW 
images [45–48]. 
Although the majority of our patients were not dis-
tinguishable from sporadic cases by means of MRI, the 
finding of thalamic hyperintensity in five out of eight 
MM homozygous patients is notable. According to pre-
vious literature reports, thalamic hyperintensity appears 
to be rather typical of MV2 type sporadic CJD and atyp-
ical of MM homozygous sCJD patients [49–51]. However, 
as only small patient groups have been studied so far 
with limited numbers of DW images, it remains to be 
confirmed that thalamic hyperintensity is rather not 
typical of MM homozygous sporadic CJD. 
From the clinical point of view, sporadic CJD cases 
with MM homozygosity may present with rapidly pro-
gressive dementia (MM1 individuals), rather slowly de-
veloping cognitive signs (MM2-cortical individuals) or 
early ataxia (MM2-thalamic individuals with variable 
disease onset). The latter patients, who clinically most 
resemble our iatrogenic patients, are however well dis-Ta
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tinguished by MRI, as signal abnormalities are usually 
not observed in this particularly rare disease type. In 
MM2-cortical individuals, signal increase was mainly 
found in the cortex (Table 5) [7, 9, 22, 30, 31, 34, 44, 50–
54].
Variant CJD patients, who may also present with early 
psychiatric signs and gait ataxia, may be differentiated 
from our cases by the presence of the pulvinar sign on 
the MRI. In the early disease stages, this finding may 
however be missing and follow-up exams should thus be 
performed [22]. Finally, a typical history of surgery may 
shift the diagnosis to iatrogenic CJD rather than spo-
radic or variant (Table 5) [7, 9, 22, 30, 31, 34, 44, 50–54]. 
Three of our MM homozygous patients did not show 
thalamic signal increase on the MRI. This might be ex-
plained by the MR examination time point and applied 
MR sequences, as thalamic signal changes were mainly 
seen in the later disease stages and on PDw images. Al-
though the PDw sensitivity for thalamic hyperintensity 
has been reported to be high, it should be considered 
that information on the specificity of this sequence is 
very limited [22, 47].
Thalamic hyperintensity has also been reported in a 
Japanese dura recipient (MM type), four growth hor-
mone recipients (two MV types, one VV type and one 
with unknown genotype) and one case of vCJD after 
blood transfusion (MM type) [9, 55, 56]. In conclusion, 
we have to consider the possibility that thalamic hyper-
intensity might be a peculiarity of acquired CJD forms.
In line with other studies, our patients were mainly 
MM homozygous at codon 129 of the PRNP [1, 11, 12, 
26]. The prevalence of MM or VV homozygosity in iCJD 
has been discussed as due to increased susceptibility.
Methionine and valine homozygosity are associated 
with shorter incubation periods in iCJD [1, 57–59]. How-
ever, in DM-CJD cases, no such influence was found [60]. 
Compared to other reports, the incubation periods ob-
served in our patients were significantly prolonged 
(mean 18 years vs. 8 years), which may be best explained 
by the fact that German CJD surveillance was only first 
established in 1993 [11]. Iatrogenic CJD cases with 
shorter incubation periods were thus probably missed. 
No clear correlation between the original graft loca-
tion, the clinical syndrome and the MRI signal altera-
tions was found, which may be due to varying examina-
tion time points and techniques or may indicate the 
independence of MRI signal alterations in iatrogenic 
CJD. Another possibility to discuss is that the clinical 
syndrome and MRI changes might be functions of the 
infectious agent’s characteristics rather than the site of 
inoculation. 
DM-CJD cases have recently been divided into a 
plaque type and non-plaque type on the basis of clinico-
pathological findings. The plaque type usually presents 
with ataxia, whereas classic CJD features are found in the 
non-plaque type [24]. MRI hyperintensities were fre-
quent in both types (not described in detail). In our 
study group, neuropathological data were limited and 
only one patient with florid plaques was found. This case 
presented with isolated ataxia, and the MRI showed hy-
perintensities of the cortex, basal ganglia and thala-
mus. 
Summarizing, the MRI findings in DM-CJD are simi-
lar to sporadic CJD, showing frequent cortex and basal 
ganglia involvement. Thalamic hyperintensities in MM 
homozygotes might however be suggestive of an iatro-
genic CJD form, rather than sporadic.
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Table 5  Disease phenotypes in sporadic and iatrogenic CJD with MM genotype
Sporadic CJD Iatrogenic CJD
Classic variant Atypical variants with MM genotype Dura mater-associated vCJD
Genotype + PrPSc type 1 or 2 MM1a MM2 – corticalb MM2 – thalamicc MM1d MM1e
Infectious mode – – – Superficial Oral
Age (median) 68 years (31–89) 67 years (60–82) 61 years (30–71) 56 years (19–79) 30 years (mean) (15–52)
Clinical onset Dementia Dementia Variable Ataxia Ataxia
MRI signal increase Cortex and 
basal ganglia
Cortex None Cortex, basal ganglia,
thalamus
Cortex, basal ganglia,
thalamus
a [52] Collins et al. 2006; b [50] Krasnianski et al. 2006, [51] Hamaguchi et al. 2005; c 7 cases reported [51] Hamaguchi et al. 2005, [44] Shiga et al. 2004, [53] Yamashita et al. 
2001; d 5 literature cases ([31] Kopp et al. 1996, [30] Hannah et al. 2001, [34] Nishida et al. 2002, [33] Mochizuki et al. 2003, [9] Wakisaka et al. 2006) and 3 own cases; e [54] 
Zeidler et al. 2000, [22] Collie et al. 2003
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